U.S. Clinical Laboratory Services Market Revenue Expansion and Share Analysis
U.S. Clinical Laboratory Services Market Revenue Expansion and Share Analysis
Clinical laboratory services encompass testing activities that generate information used by healthcare professionals in patient care. The market includes a broad range of testing categories, from clinical chemistry and hematology to genetic testing, microbiology, and cytology. These services are delivered through different provider settings, including hospital-based, stand-alone, and clinic-based laboratories. The combination of testing needs, payment sources, patient demographics, and provider models shapes the structure of the U.S. clinical laboratory services market. It also reflects varied testing needs.
Clinical laboratory services play a central role in healthcare by supporting diagnosis, monitoring, and disease management through laboratory testing. In the U.S., demand for these services is supported by healthcare expenditure, regular body check-ups, long-term disorders, chronic and infectious diseases, and the growing burden of diagnostic procedures. Increasing awareness of early diagnosis and reimbursement support from public and private sectors are also contributing to adoption.
According to Fortune Business Insights, the U.S. clinical laboratory services market size was worth USD 101.73 billion in 2023 and is projected to grow at a CAGR of 7.3% during the forecast period. The market study covers test types, age groups, sources of payment, and service providers, providing a detailed view of the factors shaping the U.S. market.
Laboratory Corporation of America (U.S.)
Quest Diagnostics Incorporated (U.S.)
Illumina, Inc. (U.S.)
Eurofins Scientific (Luxembourg)
UNILABS (A.P. Moller Holding A/S) (Switzerland)
NeoGenomics Laboratories, Inc. (U.S.)
ARUP Laboratories (U.S.)
Sonic Healthcare Limited (Australia)
Advancements in laboratory automation are an important trend in the U.S. clinical laboratory services market. Prominent companies are increasingly focusing on automated clinical diagnostic laboratories and healthcare systems. Automation techniques and advanced machinery have become increasingly prevalent across clinical laboratory services. In September 2022, Scitara Corporation announced a partnership with Agilent Technologies, Inc. to integrate its Scientific Integration Platform with Agilent’s Software and Informatics Division portfolio, including chromatography software and laboratory workflow management solutions.
The growing prevalence of chronic and infectious diseases is supporting demand for clinical laboratory services. Conditions including cystic fibrosis, sickle cell disease, Down syndrome, and breast cancer are associated with increased demand for diagnostic testing. The rise in hospitalizations and clinical laboratory tests prescribed by medical practitioners is also contributing to market growth. Fortune Business Insights cites the availability of genetic testing in the U.S. as another indicator of demand for early diagnosis.
Pricing pressure remains a key restraint. Increasing demand for clinical laboratory tests may be affected by deep discounting and pricing practices in the diagnostic industry. The report notes that affordability concerns can lead people to defer healthcare, delay or cancel medical procedures, or avoid filling prescriptions. These pressures may limit market expansion during the forecast period.
The competitive landscape includes established and emerging service companies. Laboratory Corporation of America, Quest Diagnostics Incorporated, and Eurofins Scientific held leading positions in 2022, supported by broad service portfolios and established positions in the U.S. market. Other companies with a significant presence include Illumina, ARUP Laboratories, NeoGenomics Laboratories, and Sonic Healthcare. Strategic initiatives are expected to support companies in strengthening their market presence.
Recent industry developments illustrate continued activity among market participants. In March 2023, Illumina and Myriad Genetics expanded their strategic partnership to broaden access to oncology Homologous Recombination Deficiency testing in the U.S. In July 2022, Laboratory Corporation of America began testing for monkeypox using the CDC orthopoxvirus test. In May 2022, the company announced the acquisition of diagnostic clinical laboratory services from AtlantiCare in Southern New Jersey.
By Test Type (Clinical Chemistry, Hematology, Genetic Testing, Microbiology & Cytology, and Others)
By Age (Pediatric and Adult)
By Source of Payment (Public, Private, and Out of Pocket)
and By Service Provider (Hospital-based Laboratories, Stand-alone Laboratories, Clinic-based Laboratories, and Others)
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/u-s-clinical-laboratory-services-market-107909
The report focuses specifically on the U.S. market and examines factors influencing clinical laboratory services across the country. Demand is connected with healthcare expenditure, regular health check-ups, chronic and infectious disease prevalence, diagnostic procedures, early diagnosis awareness, and reimbursement support. The market analysis also considers developments in laboratory automation and changes in clinical testing demand.
The future of the U.S. clinical laboratory services market is linked to increasing demand for diagnosis and monitoring of chronic and infectious diseases, continued adoption of laboratory automation, and strategic initiatives by service providers. Growth in diagnostic testing requirements and emphasis on early diagnosis are expected to remain important market factors. At the same time, pricing pressure and affordability concerns may influence market expansion. The report’s segmentation across test type, age, source of payment, and service provider provides a framework for understanding future market opportunities and developments.
Uncover Japan’s Market Trends - Explore the Latest -U.S. Clinical Laboratory Services Market- Insights